Topic: MEDICA

Alzheimer's disease (AD) presents a complex challenge, increasingly linked to the gut microbiota’s role in its development. This study examines changes in the gut microbiome of AD patients, focusing on the reduction of certain bacteroides strains and their metabolite, MEDICA, known for anti-inflammatory effects. However, its direct influence on AD pathology is unclear. We suggest that MEDICA supplementation might improve cognitive function by interacting with the brain-gut axis. To explore this, we assessed the impact of MEDICA on amyloid plaque formation and neuroinflammation. Our results ind